Human Recombinant Insulin Market Insights
The Global Human Recombinant Insulin market is expected to grow at a significant CAGR during the forecast period. Factors such as increasing prevalence of diabetes over the world and rising investment in medical research are expected to boost growth in the human recombinant insulin market. Recombinant Insulin is basically synthetic insulin which is developed using recombinant DNA technology. This insulin is produced by harvesting proteins in the Escherichia coli (E.coli) bacteria.
However, factors such as high cost of recombinant insulin in the market, lack of awareness about new technology and risks associated with the use of recombinant insulin are expected to have a negative impact on the growth in human recombinant insulin market.
Human Recombinant Insulin Market: Product Type Insights
On the basis of material type, the Human Recombinant Insulin market can be classified into Rapid-Acting Human Insulin, Short-Acting Human Insulin, Intermediate-Acting Human Insulin, Long-Acting Human Insulin and Premixed Human Insulin. The long-acting human insulin segment is projected to hold the largest market share in terms of revenue in the market during through the forecast period. This can be attributed to the ability of long-acting insulin to control blood sugar levels through the entire day. This type of insulin is primarily used for patients with chronic diabetic conditions, in order to keep it under control. Rapid-acting insulin is expected to hold the second largest market share, followed by the premixed human insulin segment.
Human Recombinant Insulin Market: Distribution Channel Insights
The Global Human Recombinant Insulin market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies based on the distribution channel. The retail pharmacies segment is forecasted to hold the major market share followed by the hospital pharmacies segment. The online pharmacies segment is projected to grow at the highest CAGR owing to rising popularity and convenience of online medicine purchases.
Human Recombinant Insulin Market: Brand Insights
Based on the brand, the human recombinant insulin market is classified into Insuman, Humulin, and Novolin, among others.
Human Recombinant Insulin Market: Regional Insights
North America is expected to hold the largest market share in terms of revenue in the Human Recombinant Insulin market owing to growing prevalence of diabetes in the U.S. Rapid technological advancement and investment in medical research in diabetes is further expected to contribute to the growth of human recombinant insulin market in the region. The Asia Pacific region is projected to demonstrate rapid growth in the human recombinant insulin market. This growth can be attributed to a high diabetic population in countries such as India, China, and other developing countries. Growing awareness about modern medicine is expected to positively impact the market for human recombinant insulin in the region.
Human Recombinant Insulin Market: End-Use Landscape
The end-use landscape entails a list of current and prospective consumers prevailing across the regions. This section provides company addresses, contact details, products, and regional presence of companies who are purchasing or are likely to purchase controlled release fertilizer over the coming years. Some leading consumers of controlled release fertilizer are LifePoint Health, Prime Healthcare Services, and Cipla among others.
Human Recombinant Insulin: Vendor Landscape
The report contains a chapter dedicated to vendors operating in the market, covering raw material manufactures, equipment developers, manufacturers, and distributors. The report provides these insights on a regional level. This section of the report entails contact details, experience, products manufactured/supplied, and geographical presence of companies.
Human Recombinant Insulin: Share & Competitor Analysis
Some of the key players operating in the Human Recombinant Insulin market are Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Laboratories Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd., and Dongbao Enterprise Group Co., Ltd. among others.
In June 2018, Eli Lilly and Company came up with a helpline for providing assistance to patients who require financial assistance for their insulin needs. The helpline is called Lily Diabetes Solution Center.
In June 2018, Eli Lilly and Company’s product- Humulin R U-500 showed greater reduction in A1C as compared to multiple daily injections when administered to adults with type 2 diabetes.
In September 2017, Biocon Limited received funding from the Juvenile Diabetes Research Foundation (JDRF) for their study involving evaluation of the oral insulin drug Tregopil in patients with type 1 diabetes.